Premium
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
Author(s) -
Bocchetta Martina,
Galluzzi Samantha,
Kehoe Patrick Gavin,
Aguera Eduardo,
Bernabei Roberto,
Bullock Roger,
Ceccaldi Mathieu,
Dartigues JeanFrançois,
Mendonça Alexandre,
Didic Mira,
Eriksdotter Maria,
Félician Olivier,
Frölich Lutz,
Gertz HermannJosef,
Hallikainen Merja,
Hasselbalch Steen G.,
Hausner Lucrezia,
Heuser Isabell,
Jessen Frank,
Jones Roy W.,
Kurz Alexander,
Lawlor Brian,
Lleo Alberto,
MartinezLage Pablo,
Mecocci Patrizia,
Mehrabian Shima,
Monsch Andreas,
Nobili Flavio,
Nordberg Agneta,
Rikkert Marcel Olde,
Orgogozo JeanMarc,
Pasquier Florence,
Peters Oliver,
Salmon Eric,
SánchezCastellano Carmen,
Santana Isabel,
Sarazin Marie,
Traykov Latchezar,
Tsolaki Magda,
Visser Pieter Jelle,
Wallin Åsa K.,
Wilcock Gordon,
Wilkinson David,
Wolf Henrike,
Yener Görsev,
Zekry Dina,
Frisoni Giovanni B.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.06.006
Subject(s) - medicine , biomarker , neurodegeneration , positron emission tomography , cerebrospinal fluid , amyloidosis , amyloid (mycology) , atrophy , pathology , oncology , disease , neuroimaging , radiology , psychiatry , biochemistry , chemistry
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG‐PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it “always/frequently”) followed by CSF markers (22%), FDG‐PET (16%), and amyloid‐PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as “moderate”. Seventy‐nine percent of responders felt “very/extremely” comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal ( P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.